Influence of Comorbidities on Healthcare Expenditures and Perceived Physical and Mental Health Status Among Adults with Multiple Sclerosis: A Propensity Score-Matched US National-Level Study

References

• Wallin MT, Culpepper WJ, Campbell JD, et al. The prevalence of MS in the United States: a population-based estimate using health claims data. Neurology. 2019;92(10):e1029–e1040. doi:10.1212/WNL.0000000000007035
   PubMed Web of Science ®Google Scholar
• Marrie RA, Cohen J, Stuve O, et al. A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler. 2015;21(3):263–281. doi:10.1177/1352458514564491
   PubMed Web of Science ®Google Scholar
• Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity delays diagnosis and increases disability at diagnosis in MS. Neurology. 2009;72(2):117–124. doi:10.1212/01.wnl.0000333252.78173.5f
   PubMed Web of Science ®Google Scholar
• Tettey P, Siejka D, Simpson S, et al. Frequency of comorbidities and their association with clinical disability and relapse in multiple sclerosis. Neuroepidemiology. 2016;46(2):106–113. doi:10.1159/000442203
   Web of Science ®Google Scholar
• Marrie RA, Rudick R, Horwitz R, et al. Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis. Neurology. 2010;74(13):1041–1047. doi:10.1212/WNL.0b013e3181d6b125
   PubMed Web of Science ®Google Scholar
• Berrigan LI, Fisk JD, Patten SB, et al. Health-related quality of life in multiple sclerosis: direct and indirect effects of comorbidity. Neurology. 2016;86:1417–1424. doi:10.1212/WNL.0000000000002564
   PubMed Web of Science ®Google Scholar
• Zhang T, Tremlett H, Leung S, et al. Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis. Neurology. 2016;86(14):1287–1295. doi:10.1212/WNL.0000000000002543
   PubMed Web of Science ®Google Scholar
• Tarrants M, Oleen-Burkey M, Castelli-Haley J, Lage MJ. The impact of comorbid depression on adherence to therapy for multiple sclerosis. Mult Scler Int. 2011;2011:271321. doi:10.1155/2011/271321
   PubMedGoogle Scholar
• Culpepper WJ. The incidence and prevalence of comorbidity in multiple sclerosis. Mult Scler. 2015;21(3):261–262. doi:10.1177/1352458515574151
   Web of Science ®Google Scholar
• Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler. 2015;21(3):282–293. doi:10.1177/1352458514564490
   PubMed Web of Science ®Google Scholar
• Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of cancer in multiple sclerosis. Mult Scler. 2015;21(3):294–304. doi:10.1177/1352458514564489
   PubMed Web of Science ®Google Scholar
• Marrie RA, Reingold S, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. Mult Scler. 2015;21(3):305–317. doi:10.1177/1352458514564487
   PubMed Web of Science ®Google Scholar
• Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. Mult Scler. 2015;21(3):318–331. doi:10.1177/1352458514564485
   PubMed Web of Science ®Google Scholar
• Marrie RA, Reider N, Stuve O, et al. The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review. Mult Scler. 2015;21(3):332–341. doi:10.1177/1352458514564488
   PubMed Web of Science ®Google Scholar
• Marrie RA, Reider N, Cohen J, et al. A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. Mult Scler. 2015;21(3):342–349. doi:10.1177/1352458514564486
   PubMed Web of Science ®Google Scholar
• Capkun G, Dahlke F, Lahoz R, et al. Mortality and comorbidities in patients with multiple sclerosis compared with a population without multiple sclerosis: an observational study using the US Department of Defense administrative claims database. Mult Scler Relat Disord. 2015;4(6):546–554. doi:10.1016/j.msard.2015.08.005
   PubMed Web of Science ®Google Scholar
• Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T. Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler. 2008;14(8):1091–1098. doi:10.1177/1352458508092263
   PubMed Web of Science ®Google Scholar
• Newland P, Jensen MP, Budhathoki C, Lorenz R. Secondary health conditions in individuals with multiple sclerosis: a cross-sectional web-based survey analysis. J Neurosci Nurs. 2015;47(3):124–130. doi:10.1097/JNN.0000000000000130
   Web of Science ®Google Scholar
• Redelings MD, McCoy L, Sorvillo F. Multiple sclerosis mortality and patterns of comorbidity in the United States from 1990 to 2001. Neuroepidemiology. 2006;26(2):102–107. doi:10.1159/000090444
   PubMed Web of Science ®Google Scholar
• Earla JR, Thornton JD, Hutton GJ, Aparasu RR. Marginal health care expenditure burden among U.S. civilian noninstitutionalized individuals with multiple sclerosis: 2010–2015. J Manag Care Spec Pharm. 2020;26(6):741–749. doi:10.18553/jmcp.2020.26.6.741
   Web of Science ®Google Scholar
• Campbell JD, Ghushchyan V, Brett McQueen R, et al. Burden of multiple sclerosis on direct, indirect costs and quality of life: national US estimates. Mult Scler Relat Disord. 2014;3(2):227–236. doi:10.1016/j.msard.2013.09.004
   PubMed Web of Science ®Google Scholar
• Sommers J. An examination of state estimates using multiple years of data from the medical expenditure panel survey, household component. 2006: agency for healthcare research and quality working paper no. 06004; 2006. Available from: https://meps.ahrq.gov/data_files/publications/workingpapers/wp_06004.pdf. Accessed March 25, 2021.
   Google Scholar
• Agency for Healthcare Research and Quality (AHRQ). Medical expenditure panel survey: medical care provider participants’ corner - confidentiality/HIPAA; 2021. Available from: https://meps.ahrq.gov/communication/participants/confidentialitymcp.shtml. Accessed April 8, 2021.
   Google Scholar
• Machlin S, Cohen J, Elixhauser A, Beauregard K, Steiner C. Sensitivity of household reported medical conditions in the medical expenditure panel survey. Med Care. 2009;47(6):618–625. doi:10.1097/MLR.0b013e318195fa79
   Google Scholar
• Agency for Healthcare Research and Quality (AHRQ). Healthcare cost and utilization project – HCUP A federal-state-industry partnership in health data (Clinical Classifications Software (CCS) 2014); 2014. Available from: https://www.hcup-us.ahrq.gov/toolssoftware/ccs/CCSUsersGuide.pdf. Accessed March 26, 2021.
   Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi:10.1080/00273171.2011.568786
   PubMed Web of Science ®Google Scholar
• Burea of Labor Statistics (BLS); 2021. Available from:https://www.bls.gov/cpi/factsheets/. Accessed March 25, 2021.
   Google Scholar
• MEPS HC-155. 2012 full year consolidated data file. MEPS data documentation: pain definition 2012; 2012. Available from: http://meps.ahrq.gov/mepsweb/data_stats/download_data/pufs/h155/h155doc.pdf. Accessed March 23, 2021.
   Google Scholar
• Fortin M, Dubois MF, Hudon C, Soubhi H, Almirall J. Multimorbidity and quality of life: a closer look. Health Qual Life Outcomes. 2007;5:52. doi:10.1186/1477-7525-5-52
   PubMed Web of Science ®Google Scholar
• Vyas A, Pan X, Sambamoorthi U. Chronic condition clusters and polypharmacy among adults. Int J Family Med. 2012;2012:193168. doi:10.1155/2012/193168
   PubMedGoogle Scholar
• Meduru P, Helmer D, Rajan M, Tseng CL, Pogach L, Sambamoorthi U. Chronic illness with complexity: implications for performance measurement of optimal glycemic control. J Gen Intern Med. 2007;22(Suppl 3):408–418. doi:10.1007/s11606-007-0310-5
   Web of Science ®Google Scholar
• James GWD, Hastie T, Tibshirani R. An Introduction to Statistical Learning: With Applications in R. 7th printing 2017 ed. Springer; 2013.
   Google Scholar
• Simpson RJ, McLean G, Guthrie B, Mair F, Mercer SW. Physical and mental health comorbidity is common in people with multiple sclerosis: nationally representative cross-sectional population database analysis. BMC Neurol. 2014;14:128. doi:10.1186/1471-2377-14-128
   PubMed Web of Science ®Google Scholar
• Persson R, Yood MU, Wagner M, et al. Increased risk of comorbidities in patients before and after multiple sclerosis diagnosis and initiation of treatment: a study using the US department of defense database. Neurology. 2019;92(15).
   Web of Science ®Google Scholar
• Barzola-Castro N, Cepeda-Escalante RE, Jimenez-Zambrano JA, Burgos-Campuzano AD, Acuña-Chong MG. Do anxiety and depression levels interfere with cognitive performance in Ecuadorian multiple sclerosis patients? - A case-control study. Multiple Scleros J. 2019;25:130.
   Web of Science ®Google Scholar
• Scherder R, Kant N, Wolf ET, Pijnenburg B, Scherder EJ. Psychiatric and physical comorbidities and pain in patients with multiple sclerosis. J Pain Res. 2018;11:325–334. doi:10.2147/JPR.S146717
   Web of Science ®Google Scholar
• Whitehouse CE, Fisk JD, Bernstein CN, et al. Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. Neurology. 2019;92:e406–e417. doi:10.1212/WNL.0000000000006854
   Web of Science ®Google Scholar
• Marrie RA, Walld R, Bolton JM, et al. Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiol Psychiatr Sci. 2019;28(3):333–342. doi:10.1017/S2045796017000579
   Web of Science ®Google Scholar
• Leavitt V, Tosto G, Riley C. Cognitive signatures of depression and anxiety in multiple sclerosis. Neurology. 2019;92(15).
   Web of Science ®Google Scholar
• Latas M, Vucinic latas D, Spasic Stojakovic M. Anxiety disorders and medical illness comorbidity and treatment implications. Curr Opin Psychiatry. 2019;32(5):429–434. doi:10.1097/YCO.0000000000000527
   PubMed Web of Science ®Google Scholar
• Hoang H, Laursen B, Stenager EN, Stenager E. Psychiatric co-morbidity in multiple sclerosis: the risk of depression and anxiety before and after MS diagnosis. Mult Scler. 2016;22(3):347–353. doi:10.1177/1352458515588973
   PubMed Web of Science ®Google Scholar
• Marrie RA, Fisk JD, Tremlett H, et al. Differences in the burden of psychiatric comorbidity in MS vs the general population. Neurology. 2015;85(22):1972–1979. doi:10.1212/WNL.0000000000002174
   PubMed Web of Science ®Google Scholar
• Simpson RJ, McLean G, Guthrie B, Mair F, Mercer SW. Physical and mental health comorbidity is common in people with multiple sclerosis: nationally representative cross-sectional population database analysis. BMC Neurol. 2014;14(1).
   Web of Science ®Google Scholar
• Zhang T, Zullo AR, Shireman TI. Effects of comorbidities on functional decline in nursing home residents with multiple sclerosis. J Am Geriatr Soc. 2018;66:S138. doi:10.1111/jgs.15264
   Web of Science ®Google Scholar
• Tauil CB, Grippe TC, Dias RM, et al. Suicidal ideation, anxiety, and depression in patients with multiple sclerosis. Arq Neuropsiquiatr. 2018;76(5):296–301. doi:10.1590/0004-282x20180036
   Web of Science ®Google Scholar
• Janssens AC, Buljevac D, van Doorn PA, et al. Prediction of anxiety and distress following diagnosis of multiple sclerosis: a two-year longitudinal study. Mult Scler. 2006;12(6):794–801. doi:10.1177/1352458506070935
   PubMed Web of Science ®Google Scholar
• Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010;16(9):703–712. doi:10.18553/jmcp.2010.16.9.703
   PubMed Web of Science ®Google Scholar
• Franklin MA, Happe LE, Dillman R, Marshall LZ. Frequency and economic impact of comorbid cardiac conditions with multiple sclerosis. J Manag Care Special Pharm. 2014;20(8):795–799. doi:10.18553/jmcp.2014.20.8.795
   Web of Science ®Google Scholar
• Alsallom F, Woodson S, Briggs F, Serra A, Abboud H. Impact of multiple comorbidities on eds at presentation in patients with multiple sclerosis: a cross-sectional study. Neurology. 2018;90(15).
   Google Scholar
• Gill S, Santo J, Blair M, Morrow SA. Depressive symptoms are associated with more negative functional outcomes than anxiety symptoms in persons with multiple sclerosis. J Neuropsychiatry Clin Neurosci. 2019;31(1):37–42. doi:10.1176/appi.neuropsych.18010011
   Web of Science ®Google Scholar
• Golan D, Doniger GM, Wissemann K, et al. The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis. Multiple Scleros J. 2017;24:196–204. doi:10.1177/1352458517695470
   Web of Science ®Google Scholar
• Gascoyne CR, Simpson S, Chen J, van der Mei I, Marck CH. Modifiable factors associated with depression and anxiety in multiple sclerosis. Acta Neurol Scand. 2019;140(3):204–211. doi:10.1111/ane.13132
   PubMed Web of Science ®Google Scholar
• Rijken M, van Kerkhof M, Dekker J, Schellevis FG. Comorbidity of chronic diseases: effects of disease pairs on physical and mental functioning. Qual Life Res. 2005;14(1):45–55. doi:10.1007/s11136-004-0616-2
   PubMed Web of Science ®Google Scholar
• Haggerty JJ, Prange AJ. Borderline hypothyroidism and depression. Annu Rev Med. 1995;46:37–46. doi:10.1146/annurev.med.46.1.37
   PubMed Web of Science ®Google Scholar